Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Lyell Immunopharma, Inc. (LYEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 864.49 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-12
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 260.00K shares, a 111.38% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 910.00K shares, a 4.27% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 2.50M shares, a 67.65% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 864.49K shares, a 76.42% decline from fiscal 2024.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.67M shares, a 70.44% decline from fiscal 2023.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 12.40M shares, a 32.61% decline from fiscal 2022.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 18.40M shares, a 42.11% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 864.49K shares 10-K · filed 2026-03-12 | |||
| 2024-12-31 | 260.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 260.00K shares derived: sum of 2 quarters · filed 2025-03-11 | 1.17M shares derived: sum of 3 quarters · filed 2025-03-11 | 3.67M shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 910.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 3.41M shares 10-Q · filed 2024-11-07 | 3.53M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 910.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 3.41M shares 10-Q · filed 2024-08-07 | 3.53M shares derived: sum of 3 quarters · filed 2024-08-07 | 7.22M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 2.50M shares 10-Q · filed 2024-05-06 | 2.62M shares derived: sum of 2 quarters · filed 2024-05-06 | 6.31M shares derived: sum of 3 quarters · filed 2024-05-06 | 7.18M shares derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | 123.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 3.81M shares derived: sum of 2 quarters · filed 2024-02-28 | 4.69M shares derived: sum of 3 quarters · filed 2024-02-28 | 12.40M shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 3.69M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 4.56M shares derived: sum of 2 quarters · filed 2023-11-07 | 12.28M shares 10-Q · filed 2023-11-07 | 20.74M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 872.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 8.59M shares 10-Q · filed 2023-08-08 | 17.05M shares derived: sum of 3 quarters · filed 2023-08-08 | 17.53M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 7.71M shares 10-Q · filed 2023-05-04 | 16.18M shares derived: sum of 2 quarters · filed 2023-05-04 | 16.65M shares derived: sum of 3 quarters · filed 2023-05-04 | 18.15M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 8.47M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 8.94M shares derived: sum of 2 quarters · filed 2023-02-28 | 10.44M shares derived: sum of 3 quarters · filed 2023-02-28 | 18.40M shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 472.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 1.97M shares derived: sum of 2 quarters · filed 2022-11-08 | 9.93M shares 10-Q · filed 2022-11-08 | 10.36M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 1.50M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 9.46M shares 10-Q · filed 2022-08-04 | 9.89M shares derived: sum of 3 quarters · filed 2022-08-04 | 11.70M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 7.96M shares 10-Q · filed 2022-05-10 | 8.39M shares derived: sum of 2 quarters · filed 2022-05-10 | 10.20M shares derived: sum of 3 quarters · filed 2022-05-10 | |
| 2021-12-31 | 426.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 2.24M shares derived: sum of 2 quarters · filed 2022-03-29 | 12.95M shares 10-K · filed 2022-03-29 | |
| 2021-09-30 | 1.81M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 12.52M shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 10.71M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |